Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crizotinib in ROS1-positive advanced lung adenocarcinoma
2013-002737-38Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by University of Cologne. Primary endpoint: Objective response rate. Started Feb 2014; status: completed.
02
Drugs
crizotinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2013-002737-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002737-38.